US5830504A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cooperative combinations of ligands contained within a matrix
Assignee: Sanford Burnham Prebys Medical Discovery Institute
•
Filing: 1995-06-01
•
Granted: 1998-11-03
•
Expires: 2015-06-01
Abstract
Abstract The present invention provides compositions and methods for promoting cell migration and tissue regeneration. The composition contains a ligand for the alpha v beta 3 integrin and a ligand for the insulin receptor, the PDGF receptor, the IL-4 receptor, or the IGF receptor, combined in a matrix. The combination of alpha v beta 3 ligand and growth factor produces an unexpected synergistic effect in enhancing wound healing compared with the effect of each component separately. The present invention also provides a method of wound healing and a method of inducing tissue regeneration by applying the compositions of the present invention to the site of the wound.
Inventors
- 👤 Kristiina Vuori
- 👤 Erkki I. Ruoslahti
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:43
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/0068; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6435; A61L; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0047; A61L26/0052; A61P; A61P17/00; C07; C07K; C07K14/00; C07K14/435; C07K14/78; C07K2319/00; C12N2533/00; C12N2533/50; C12N2533/70; C12N2533/80
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
101 words
A method of treating a wound comprising placing into the wound a composition comprising a substantially purified first ligand to an α v β 3 integrin and a substantially purified second ligand selected from the group consisting of a ligand to a PDGF receptor, a ligand to an insulin receptor, a ligand to an IL-4 receptor, and a ligand to an insulin-like growth factor receptor, wherein said first ligand and said second ligand are incorporated within a matrix, and wherein the combination of said first ligand and said second ligand results in a synergistic effect on cell proliferation or cell migration.
Claim 2
Independent Claim
101 words
A method of treating a wound comprising placing into the wound a composition comprising a substantially purified first ligand to an α v β 3 integrin and a substantially purified second ligand selected from the group consisting of a ligand to a PDGF receptor, a ligand to an insulin receptor, a ligand to an IL-4 receptor, and a ligand to an insulin-like growth factor receptor, wherein said first ligand and said second ligand are incorporated within a matrix, and wherein the combination of said first ligand and said second ligand results in a synergistic effect on cell proliferation or cell migration.
Claim 3
Independent Claim
83 words
A method of treating a wound comprising placing into the wound a composition comprising (a) a first ligand to an α V β 3 integrin consisting of G(dR) (dR) (dR) (dR) (dR)GGG(dR)GDSPASSK (Seq ID No. 1); (b) a matrix consisting of hyaluronic acid conjugated to said first ligand to form a synthetic matrix semi-gel; and (c) a second ligand associated with said synthetic matrix semi-gel and selected from the group consisting of insulin, insulin-like growth factor, IL-4, PDGF and biologically active analogs thereof.
Claim 4
Independent Claim
83 words
A method of treating a wound comprising placing into the wound a composition comprising (a) a first ligand to an α V β 3 integrin consisting of G(dR) (dR) (dR) (dR) (dR)GGG(dR)GDSPASSK (Seq ID No. 1); (b) a matrix consisting of hyaluronic acid conjugated to said first ligand to form a synthetic matrix semi-gel; and (c) a second ligand associated with said synthetic matrix semi-gel and selected from the group consisting of insulin, insulin-like growth factor, IL-4, PDGF and biologically active analogs thereof.
Claim 5
Independent Claim
103 words
A method of inducing or enhancing tissue regeneration comprising placing into a wound a composition comprising a substantially purified first ligand to an α v β 3 integrin and a substantially purified second ligand selected from the group consisting of a ligand to a PDGF receptor, a ligand to an insulin receptor, a ligand to an IL-4 receptor, and a ligand to an insulin-like growth factor receptor, wherein said first ligand and said second ligand are incorporated within a matrix, and wherein the combination of said first ligand and said second ligand results in a synergistic effect on cell proliferation or cell migration.
Claim 6
Independent Claim
103 words
A method of inducing or enhancing tissue regeneration comprising placing into a wound a composition comprising a substantially purified first ligand to an α v β 3 integrin and a substantially purified second ligand selected from the group consisting of a ligand to a PDGF receptor, a ligand to an insulin receptor, a ligand to an IL-4 receptor, and a ligand to an insulin-like growth factor receptor, wherein said first ligand and said second ligand are incorporated within a matrix, and wherein the combination of said first ligand and said second ligand results in a synergistic effect on cell proliferation or cell migration.
Claim 7
Independent Claim
85 words
A method of inducing or enhancing tissue regeneration comprising placing into a wound a composition comprising (a) a first ligand to an α V β 3 integrin consisting of G(dR) (dR) (dR) (dR) (dR)GGG(dR)GDSPASSK (Seq ID No. 1); (b) a matrix consisting of hyaluronic acid conjugated to said first ligand to form a synthetic matrix semi-gel; and (c) a second ligand associated with said synthetic matrix semi-gel and selected from the group consisting of insulin, insulin-like growth factor, IL-4, PDGF and biologically active analogs thereof.
Claim 8
Independent Claim
85 words
A method of inducing or enhancing tissue regeneration comprising placing into a wound a composition comprising (a) a first ligand to an α V β 3 integrin consisting of G(dR) (dR) (dR) (dR) (dR)GGG(dR)GDSPASSK (Seq ID No. 1); (b) a matrix consisting of hyaluronic acid conjugated to said first ligand to form a synthetic matrix semi-gel; and (c) a second ligand associated with said synthetic matrix semi-gel and selected from the group consisting of insulin, insulin-like growth factor, IL-4, PDGF and biologically active analogs thereof.
References Cited (Backward Citations)
US3883393A
Cited
US4511653A
Cited
US4517686A
Cited
US4578079A
Cited
US4589881A
Cited
US4661111A
Cited
EP0142192A1
Cited
US4703108A
Cited
US4636524A
Cited
US5128326A
Cited
US4683291A
Cited
US4683291B1
Cited
US4983580A
Cited
US4760131A
Cited
WO1988003151A2
Cited
WO1988003810A1
Cited
US4885163A
Cited
EP0282317A2
Cited
JPS63264069A
Cited
US5053388A
Cited
US4857508A
Cited
US4874746A
Cited
JPH01279836A
Cited
EP0341915A2
Cited
US4973466A
Cited
US5120829A
Cited
US5196185A
Cited
JPH0680694A
Cited
EP0562862A1
Cited
EP0574880A1
Cited
EP0578083A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-02 | 2002-05-04 | 2002-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-02 | 2006-05-04 | 2006-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-02 | 2010-05-04 | 2010-11-03 | $7700.00 | Window Closed / Lapsed |